Invention Grant
- Patent Title: Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer
-
Application No.: US17556626Application Date: 2021-12-20
-
Publication No.: US11713322B2Publication Date: 2023-08-01
- Inventor: Yun Long
- Applicant: Capella Therapeutics, Inc.
- Applicant Address: US CA San Diego
- Assignee: CAPELLA THERAPEUTICS, INC.
- Current Assignee: CAPELLA THERAPEUTICS, INC.
- Current Assignee Address: US CA San Diego
- Agency: Fenwick & West LLP
- The original application number of the division: US16902184 2020.06.15
- Main IPC: C07D498/04
- IPC: C07D498/04 ; C07D491/056 ; C07D487/04 ; C07D491/04 ; A61K31/55
Abstract:
Provided herein are benzimidazole derivatives, for example, or Formula (I), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a proliferative disease.
Public/Granted literature
- US20220298167A1 BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER Public/Granted day:2022-09-22
Information query
